Behind the scenesBack to the contract between Amorfix and Biogen, maybe Section 2.2 where Biogen has an Option to Expand Licensed Field is happening. In the event Amorfix has produced a qualified study with there cancer they need to provide to Biogen notice in writing. Within 90 days Biogen will, if it wishes to exercise its Option Right, designate one or more Option indications , which shall be reasonably related to the Qualified study. Biogen and Amorfix under the Exercise of Option Right, agree to engage in such good-faith negotiations for a period of ninety (90) days....... In any event that Amorfix's proof of concept with their cancer antibodies was done under the context of a qualified study, it can be a six month process through negotiations. It looks like to me this process with Biogen needs to happen or Amorfix is in violation of their agreement...